SLC5A2 and type 2 diabetes mellitus: Considering the high numbers of our participants diagnosed with T2D (54.0% with 16.8% being on oral therapy) and given the known effect of certain drugs on MAFLD and MASH, i.e., thiazolidinediones (TZDs), sodium glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists [53], this might impact the associations reported here.